Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

The Pharmaceutical Journal

Editorial

Over 100,000 people in the UK who could benefit from palliative care do not receive it, according to a report by the London School of Economics and Political Science. Image of a nurse holding the head of a dying patient

Better information is needed to improve palliative care servicesSubscription

Gaps in access to palliative care services mean that many patients with life-limiting illnesses miss out on support they need, but there is much to learn about people’s experiences at the end of life.

Feature

A new drug inhibits an enzyme called proprotein convertase subtilisin/kexin type 9 or PCSK9, which could help lower cholesterol and reduce heart attacks. In the image, a light micrograph of cholesterol crystals

PCSK9 inhibitors: the next cholesterol-lowering blockbusters?

By

Statins have been a mainstay of heart attack and stroke prevention for the past 20 years, but the race is on to bring a new drug to market that targets an enzyme called PCSK9.

Comment

Current dietary guidelines issued by Public Health England (Department of Health) to lower risk of coronary heart disease (CHD) by eating less saturated fat have once again come under attack. But evidence still stands: its consumption should be limited

Saturated fat: guidelines to reduce coronary heart disease risk are still validSubscription

By

A debate over whether saturated fat is bad for cardiovascular health has surfaced once again. The evidence still stands: its consumption should be limited.

Learning article

Linaclotide, lubiprostone and prucalopride are some of the latest medicines for the management of constipation. In the image, barium enema x-ray of irritable bowel syndrome (IBS)

Linaclotide, lubiprostone and prucalopride interactionsSubscription

By , ,

How to avoid potential pharmacokinetic and pharmacodynamic interactions with the latest medicines for managing constipation.

Q&A

Bruce Warner, deputy chief pharmaceutical officer describes his role in promoting the medicines optimisation agenda and his views on broader issues affecting pharmacists

Bruce Warner: getting the best value and outcomes from the use of medicinesSubscription

By

Deputy chief pharmaceutical officer Bruce Warner discusses promoting the medicines optimisation agenda and shares his views on broader issues affecting pharmacists.

CPD article

Coloured 3D computed tomography (CT) scan of the abdomen of a patient with impacted bowels, which could occur in patients with untreated constipation

Constipation: managing the condition in adultsSubscription

By

How to assess patients with constipation and select the right treatment to minimise the risk of complications.

Careers

Fitness to practise can be impaired for a number of reasons including misconduct, lack of competence, ill health and conviction of a criminal offence. Here is an outline of the fitness-to-practise process

The UK fitness-to-practise process: from complaint to appealSubscription

By

If a complaint is brought against a pharmacist in the UK, what can he or she expect from the fitness-to-practise process? Ailsa Colquhoun explains.

News

Recent meta-analysis has cast doubt on the use of paracetamol as the first-line analgesic for spinal pain and osteoarthritis (pictured) of the hip and knee, as is currently recommended in clinical guidelines

Meta-analysis casts doubt over first-line paracetamol use for back pain and osteoarthritisSubscription

A meta-analysis published in The BMJ has cast doubt on the use of paracetamol as the first-line analgesic for spinal pain and osteoarthritis of the hip and knee.

Measures to limit the abuse of or risk of overdose from opioid drugs have been issued by the US Food and Drug Administration (FDA) in guidance for the pharmaceutical industry. In the image, building 66 of the FDA

FDA fights opioid abuse with industry guidanceSubscription

Measures to limit the abuse of opioid drugs have been issued by the US Food and Drug Administration in guidance for the pharmaceutical industry.

The Pharmaceutical Journal

18 April 2015, Vol 294, No 7858

Cover Story:

The race is on to bring a new drug to market that targets an enzyme called PCSK9 to fight cardiovascular disease.

Read more…

The Pharmaceutical Journal

View previous issue

YOUR RPS

Applicants are about to undergo their final assessment as the RPS Faculty prepares to accept the first pharmacists with less than ten years’ experience

Tough, costly, rewarding: how 12 pharmacists found the RPS Faculty processSubscription

By

As the RPS Faculty prepares to accept the first pharmacists with less than ten years’ experience, Stephen Robinson explores the views of those applicants about to undergo their final assessment.

Notice-board

For latest notifications, opportunities and product updates, visit the notice-board page here.

Announcements

For official announcements from The Royal Pharmaceutical society please visit the announcements page here.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.